BioSpace News Archive

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced enrollment of its first patient at one of its newest clinical sites, Columbia University New York-Presbyterian Hospital Irving Medical Center (“Columbia University”), in its ongoing TIGeR-PaC Phase 3 clinical trial.

Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases.

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the 4th Annual Chronic Kidney Disease Drug Development (CKD) Summit in Boston from March 1 - 3, 2022.

Exscientia announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO and Ben Taylor, CFO & Chief Strategy Officer, will participate in fireside chats at the following investor conferences in March:

Element Biosciences, Inc. today announced a partnership with QIAGEN to validate its leading NGS library prep and target enrichment offerings on the AVITI System.

Qualigen Therapeutics, Inc. today issues the following Letter to Shareholders:

Cerveau Technologies, Inc. (Cerveau) and Nihon Medi-Physics (NMP), a leading company for radiopharmaceuticals in Japan, today announced that they signed a manufacturing service agreement, in which Cerveau grants NMP the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent.

International Isotopes Inc. is pleased to announce it has completed an asset purchase agreement with Pharmalogic Holdings Corp. for assets contained within most of the square footage of INIS’s new contract manufacturing facility.

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today FDA clearance for its CELERIS™ single-use sinus debrider system with a full market availability in the near future.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a keynote presentation by Lidia Fonseca, Chief Digital and Technology Officer, Executive Vice President, at the Truist Securities Life Sciences AI Symposium - Biotech & Tools on Tuesday, March 1, 2022 at 12:30 p.m. Eastern Standard Time.